Estrogen & recurrent UTI: In postmenopausal women

American Journal of Nursing

Volumn 102, Issue 8, 2002, Pages 44-52

  Maloney, Cynthia ^a  

^a Seton Health System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN;

ESTROGEN THERAPY; FEMALE; HUMAN; METABOLISM; MIDDLE AGED; PHYSIOLOGY; POSTMENOPAUSE; REVIEW; URINARY TRACT INFECTION;

ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; URINARY TRACT INFECTIONS;

EID: 0036688178     PISSN: 0002936X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000446-200208000-00038     Document Type: Article

References (60)

1. Social Security Administration. Life expectancy at birth and age 65 by sex, calendar year, and alternative. http://www.ssa.gov/OACT/NOTES/AS112/tab9.html.
2. Brown JS, et al. Prevalence of urinary incontinence and associated risk factors in postmenopausal women. Obstet Gynecol 1999;94(1):66-70.
3. Stamm W. Urinary tract infections and pyelonephritis. In: Fauci AS, et al., editors. Harrison's principles of internal medicine. 14th ed. New York: McGraw-Hill; 1998. vol. 1. p. 817-24.
4. Molander U, et al. A longitudinal cohort study of elderly women with urinary tract infections. Maturitas 2000;34(2):127-31.
5. Cardozo L, et al. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 1998;92(4 Pt 2):722-7.
6. Yoshikawa TT, et al. Management of complicated urinary tract infection in older patients. J Am Geriatr Soc 1996;44(10):1235-41.
7. Stenberg A, et al. Prevalence of genitourinary and other climacteric symptoms in 61-year-old women. Maturitas 1996;24(1-2):31-6.
8. Stenberg A, et al. Prevalence of postmenopausal symptoms in two age groups of elderly women in relation to oestrogen replacement therapy. Maturitas 1999;33(3):229-37.
9. Nicolle LE. Urinary tract infections in long-term care facilities. Infect Control Hosp Epidemiol 1993;14(4):220-5.
10. Rosenberg M. Pharmacoeconomics of treating uncomplicated urinary tract infections. Int J Antimicrob Agents 1999;11(3-4):247-51; discussion 61-4.
11. Centers for Disease Control and Prevention. Urinary tract infections. 2000. http://www.cdc.gov/ncidod/dbmd/ diseaseinfo/urinarytractinfections_t.htm.
12. Smith P. Estrogens and the urogenital tract: studies on steroid hormone receptors and a clinical study on a new estradiol-releasing vaginal ring. Acta Obstet Gynecol Scand Suppl 1993;157:1-26.
13. Stamm WE, Norrby SR. Urinary tract infections: disease panorama and challenges. J Infect Dis 2001;183 Suppl 1:S1-4.
14. Engel JD, Schaeffer AJ. Evaluation of and antimicrobial therapy for recurrent urinary tract infections in women. Urol Clin North Am 1998;25(4):685-701.
15. Henriksson L, et al. A comparative multicenter study of the effects of continuous low-dose estradiol released from a new vaginal ring versus estriol vaginal pessaries in postmenopausal women with symptoms and signs of urogenital atrophy. Am J Obstet Gynecol 1994;171(3): 624-32.
16. Ayton RA, et al. A comparative study of safety and efficacy of continuous low dose oestradiol released from a vaginal ring compared with conjugated equine oestrogen vaginal cream in the treatment of postmenopausal urogenital atrophy. Br J Obstet Gynaecol 1996;103(4):351-8.
17. Barentsen R, et al. Continuous low dose estradiol released from a vaginal ring versus estriol vaginal cream for urogenital atrophy. Eur J Obstet Gynecol Reprod Biol 1997;71(1):73-80.
18. Maloney C, Oliver ML. Effect of local conjugated estrogens on vaginal pH in elderly women. J Am Directors Assoc 2001;2:51-5.
19. Griebling TL, Nygaard IE. The role of estrogen replacement therapy in the management of urinary incontinence and urinary tract infection in postmenopausal women. Endocrinol Metab Clin North Am 1997;26(2):347-60.
20. Stapleton A, Stamm WE. Prevention of urinary tract infection. Infect Dis Clin North Am 1997;11(3):719-33.
21. Fantl J, et al. Urinary incontinence in adults: acute and chronic management. Rockville (MD).
22. Chompootaweep S, et al. The use of two estrogen preparations (a combined contraceptive pill versus conjugated estrogen cream) intravaginally to treat urogenital symptoms in postmenopausal Thai women: a comparative study. Clin Pharmacol Ther 1998;64(2):204-10.
23. Henriksson L, et al. A one-year multicenter study of efficacy and safety of a continuous, low-dose, estradiol-releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging. Am J Obstet Gynecol 1996;174(1 Pt 1):85-92.
24. Cardozo L, et al. Oestriol in the treatment of postmenopausal urgency: a multicentre study. Maturitas 1993;18(1):47-53.
25. Fantl JA, et al. Efficacy of estrogen supplementation in the treatment of urinary incontinence. The Continence Program for Women Research Group. Obstet Gynecol 1996;88(5):745-9.
26. Jackson S, et al. The effect of oestrogen supplementation on post-menopausal urinary stress incontinence: a double-blind placebo-controlled trial. Br J Obstet Gynaecol 1999;106(7):711-8.
27. Cardozo L, et al. A systematic review of estrogens for recurrent urinary tract infections: third report of the hormones and urogenital therapy (HUT) committee. Int Urogynecol J Pelvic Floor Dysfunct 2001;12(1):15-20.
28. American College of Obstetricians and Gynecologists. ACOG educational bulletin: hormone replacement therapy. Washington (DC): The College; 1998. No. 247.3.
29. Palacios S. Current perspectives on the benefits of HRT in menopausal women. Maturitas 1999;33 Suppl 1:S1-13.
30. Hulley S, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280(7):605-13.
31. Tang MX, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996;348(9025):429-32.
32. Calle EE, et al. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Natl Cancer Inst 1995;87(7):517-23.
33. Seddon J. Epidemiology of age-related macular degeneration. In: Albert D, et al., editors. Principles and practice of ophthalmology. 2nd ed. Philadelphia: Saunders; 1999. p. 521-31.
34. Sherwin BB. Can estrogen keep you smart? Evidence from clinical studies. J Psychiatry Neurosci 1999;24(4):315-21.
35. Redmond GP. Hormones and sexual function. Int J Fertil Womens Med 1999;44(4):193-7.
36. Moe KE. Reproductive hormones, aging, and sleep. Semin Reprod Endocrinol 1999;17(4):339-48.
37. Maheux R, et al. A randomized, double-blind, placebo-controlled study on the effect of conjugated estrogens on skin thickness. Am J Obstet Gynecol 1994;170(2):642-9.
38. Notelovitz M, Mattox JH. Suppression of vasomotor and vulvovaginal symptoms with continuous oral 17beta-estradiol. Menopause 2000;7(5):310-7.
39. Utian WH, et al. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001;75(6): 1065-79.
40. Persson I, et al. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy: long-term follow-up of a Swedish cohort. Int J Cancer 1996;67(3):327-32.
41. Archer DF, Pickar JH. Hormone replacement therapy: effect of progestin dose and time since menopause on endometrial bleeding. Obstet Gynecol 2000;96(6):899-905.
42. Wyeth-Ayerst Laboratories. Prempro™ (conjugated estrogens tablets/medroxyprogesterone acetate tablets, USP) [prescribing information]. 2000. http://www.wyeth.com/content/ ShowFile.asp?id=133.
43. Bush TL, et al. Hormone replacement therapy and breast cancer: a qualitative review. Obstet Gynecol 2001;98(3): 498-508.
44. O'Meara ES, et al. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst 2001;93(10):754-62.
45. Notelovitz M. Estrogen therapy in the management of problems associated with urogenital aging: a simple diagnostic test and the effect of the route of hormone administration. Maturitas 1995;22 Suppl:S31-3.
46. Willhite LA, O'Connell MB. Urogenital atrophy: prevention and treatment. Pharmacotherapy 2001;21(4):464-80.
47. Foidart JM, et al. Efficacy of sustained-release vaginal oestriol in alleviating urogenital and systemic climacteric complaints. Maturitas 1991;13(2):99-107.
48. Rioux JE, et al. 17beta-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause 2000;7(3):156-61.
49. Privette M, et al. Prevention of recurrent urinary tract infections in postmenopausal women. Nephron 1988;50(1):24-7.
50. Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med 1993;329(11):753-6.
51. Handa VL, et al. Vaginal administration of low-dose conjugated estrogens: systemic absorption and effects on the endometrium. Obstet Gynecol 1994;84(2):215-8.
52. Kirkengen AL, et al. Oestriol in the prophylactic treatment of recurrent urinary tract infections in postmenopausal women. Scand J Prim Health Care 1992;10(2):139-42.
53. Eriksen B. A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. Am J Obstet Gynecol 1999;180(5):1072-9.
54. Brandberg A, et al. Low dose oral estriol treatment in elderly women with urogenital infections. Acta Obstet Gynecol Scand Suppl 1987;140:33-8.
55. Orlander JD, et al. Urinary tract infections and estrogen use in older women. J Am Geriatr Soc 1992;40(8):817-20.
56. Oliveria SA, et al. Estrogen replacement therapy and urinary tract infections in postmenopausal women aged 45-89. Menopause 1998;5(1):4-8.
57. Cardozo L, et al. Low dose oestrogen prophylaxis for recurrent urinary tract infections in elderly women. Br J Obstet Gynaecol 1998;105(4):403-7.
58. Fraser IS, et al. Vaginal epithelial surface appearances in women using vaginal rings for contraception. Contraception 2000;61(2):131-8.
59. Nachtigall LE. Comparative study: Replens versus local estrogen in menopausal women. Fertil Steril 1994;61(1):178-80.
60. Loprinzi CL, et al. Phase ni randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. J Clin Oncol 1997;15(3):969-73.